John E. (Jack) Bailey Jr.

This profile gathers the share dealings of John E. (Jack) Bailey Jr. in G1 Therapeutics, Inc., where the filings describe the role as chief executive. We count 12 filings; the first trade dates from 10 November 2020 and the latest from 18 September 2024.

On the open market, the record shows 2 purchases worth €87k and 4 sales worth €287k. On balance, insiders were net sellers of €200k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 6 share grants. So far in 2024, the count stands at no purchases and 3 sales.

On 18 September 2024 came the latest disclosure, a share grant in G1 Therapeutics, Inc. The latest purchase dates back some time: it was published 2,168 days ago, on 13 November 2020. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.